Comparison of visual acuity outcomes between ranibizumab and bevacizumab treatment in neov

Comparison of visual acuity outcomes between ranibizumab and bevacizumab treatment in neovascular age-related macular degeneration

Ian J Constable; Ian L McAllister; Timothy Isaacs

【期刊名称】《《国际眼科杂志：英文版》》 【年(卷),期】2011(000)001

【摘要】AIM:To compare visual acuity(VA) outcomes between intravitreal injection of bevacizumab and ranibizumab in the treatment of neovascular age-related macular degeneration(AMD).· METHODS:We conducted a consecutive,retrospective case series study in patients with newly diagnosed all type choroidal neovascularization(CNV) secondary to AMD who received an intravitreal injection of bevacizumab(1.25mg) or ranibizumab(0.3mg) at Lions Eye Institute,Western Australia from Mar.2006 to May 2008.All patients received injection at baseline with additional monthly injections given at the discretion of the treating physician.Main outcome measures were changes in VA.· RESULTS:There were 371 consecutive patients received injection at least in one eye with at least 6 months of follow up(median of 12.0 months).Bevacizumab treatment prevented 221 out of 278(79.5%) patients from losing <15 letters in VA compared with 79 out of 93(84.9%) of ranibizumab treated patients(P=0.25).While 68(24.5%) of bevacizumab treated patients gained ≥15 letters of VA compared with 24(25.8%) of ranibizumab